{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:11:46Z","timestamp":1789431106011,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiotherapy (RT) with immunochemotherapy (ICT) followed by CAR T-cell therapy may have synergistic effects due to cytoreduction and enhancing antigen spread, thereby inducing anti-cancer immune responses. The aim of this study was to analyze retrospective comparative data on the use of RT prior to anti-CD19 directed CAR T-cell therapy with a special focus on cytoreduction and RT related side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients aged\u2009\u2265\u200918 years with relapsed\/ refractory Large B-Cell-lymphoma (r\/r LBCL) treated with anti-CD19 CAR T-cell therapy in our institution from 05\/ 2019\u201308\/2023 were analyzed retrospectively, with the RT therapy group comprising all patients receiving RT with or without concomitant systemic therapy. The control (CO) group was manually matched on age, prior therapy lines and remission state at lymphodepletion. Post-RT tumor volumes (TV) were calculated for 6 out of 7 patients pre-CAR T and for 1 patient post-CAR T. Primary endpoints were reduction of TV and CAR T as well as RT related side effects. Secondary endpoints included overall survival (OS) and progression free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      8 patients receiving RT within 60 days prior to CAR T-cell infusion and 8 controls were included in the final analysis. 6 out of 8 patients received concomitant bridging therapy. RT alone or in combination with concomitant systemic therapy led to a significant reduction of TV (average reduction of 68%) within the radiated field from baseline to post RT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028). The combination of RT and CAR T-cell therapy was not associated with an increased rate of CAR T related side effects or complications (cytokine release syndrome\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.6, immune effector cell-associated neurotoxicity\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.2, corticosteroid use\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.9, Tocilizumab use\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.9, transfer to intensive care unit\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.6). OS and PFS did not differ between the RT- and CO-group (OS\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.64, PFS\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.35).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data indicate that RT is a feasible and effective way of cytoreduction before CAR T-cell therapy, also in combination with systemic chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-026-02822-z","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:26:55Z","timestamp":1774952815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bridging radiotherapy before anti-CD19 CAR T-cell therapy for Large B-cell lymphoma \u2013 results from a single-center study"],"prefix":"10.1186","volume":"21","author":[{"given":"Sebastian M.","family":"Stolz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"von Wachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max J.","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kreutmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weeda","family":"Mamozai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"R\u00f6sler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hockl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiwand","family":"Ahmadsei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian M.","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Motisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Schneidawind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mayinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2822_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"2822_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"2822_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"2822_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"2822_CR5","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2022.w30186","author":"S Stolz","year":"2022","unstructured":"Stolz S, et al. Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland. Swiss Med Wkly. 2022. https:\/\/doi.org\/10.4414\/smw.2022.w30186.","journal-title":"Swiss Med Wkly"},{"key":"2822_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19:342\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"2822_CR7","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:4898\u2013911.","journal-title":"Blood Adv"},{"key":"2822_CR8","doi-asserted-by":"publisher","first-page":"e817","DOI":"10.1097\/HS9.0000000000000817","volume":"7","author":"C-A Voltin","year":"2023","unstructured":"Voltin C-A, et al. Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy. HemaSphere. 2023;7:e817.","journal-title":"HemaSphere"},{"key":"2822_CR9","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","volume":"7","author":"C Roddie","year":"2023","unstructured":"Roddie C, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7:2872\u201383.","journal-title":"Blood Adv"},{"key":"2822_CR10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/bmt.2008.408","volume":"43","author":"BS Hoppe","year":"2009","unstructured":"Hoppe BS, et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transpl. 2009;43:941\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2822_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","volume":"99","author":"C Wilke","year":"2017","unstructured":"Wilke C, et al. Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma. Int J Radiat Oncol. 2017;99:94\u2013102.","journal-title":"Int J Radiat Oncol"},{"key":"2822_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","volume":"100","author":"AK Ng","year":"2018","unstructured":"Ng AK, et al. Role of Radiation Therapy in Patients With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol. 2018;100:652\u201369.","journal-title":"Int J Radiat Oncol"},{"key":"2822_CR13","doi-asserted-by":"crossref","unstructured":"Sia J, Szmyd R, Hau E, Gee HE. Molecular mechanisms of radiation-induced cancer cell death: a primer. Front Cell Dev Biol. 2020;8.","DOI":"10.3389\/fcell.2020.00041"},{"key":"2822_CR14","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria S, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol. 2004;58:862\u201370.","journal-title":"Int J Radiat Oncol"},{"key":"2822_CR15","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","volume":"26","author":"C DeSelm","year":"2018","unstructured":"DeSelm C, et al. Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. Mol Ther. 2018;26:2542\u201352.","journal-title":"Mol Ther"},{"key":"2822_CR16","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","volume":"8","author":"N Kostopoulos","year":"2024","unstructured":"Kostopoulos N, et al. Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration. Blood Adv. 2024;8:6308\u201320.","journal-title":"Blood Adv"},{"key":"2822_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijrobp.2019.02.001","volume":"104","author":"NG Mikhaeel","year":"2019","unstructured":"Mikhaeel NG, et al. The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol. 2019;104:501\u201312.","journal-title":"Int J Radiat Oncol"},{"key":"2822_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2822_CR19","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","volume":"105","author":"AJ Sim","year":"2019","unstructured":"Sim AJ, et al. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol. 2019;105:1012\u201321.","journal-title":"Int J Radiat Oncol"},{"key":"2822_CR20","doi-asserted-by":"publisher","first-page":"109580","DOI":"10.1016\/j.radonc.2023.109580","volume":"183","author":"J Fan","year":"2023","unstructured":"Fan J, et al. Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy. Radiother Oncol. 2023;183:109580.","journal-title":"Radiother Oncol"},{"key":"2822_CR21","first-page":"e2591","volume":"29","author":"H Hubbeling","year":"2023","unstructured":"Hubbeling H, et al. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed\/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy. Transpl Cell Ther. 2023;29:e2591\u201325910.","journal-title":"Transpl Cell Ther"},{"key":"2822_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.radonc.2022.08.007","volume":"175","author":"HS Ababneh","year":"2022","unstructured":"Ababneh HS, Abramson JS, Johnson PC, Patel CG. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. Radiother Oncol. 2022;175:65\u201372.","journal-title":"Radiother Oncol"},{"key":"2822_CR23","doi-asserted-by":"publisher","unstructured":"Yegya-Raman N, et al. Bridging radiotherapy prior to chimeric antigen receptor T-cells for B-cell lymphomas: an ILROG multicenter study. Blood Adv. 2025;2025015855. https:\/\/doi.org\/10.1182\/bloodadvances.2025015855.","DOI":"10.1182\/bloodadvances.2025015855"},{"key":"2822_CR24","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1182\/bloodadvances.2024013393","volume":"8","author":"GY Cederquist","year":"2024","unstructured":"Cederquist GY, et al. CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas. Blood Adv. 2024;8:5192\u20139.","journal-title":"Blood Adv"},{"key":"2822_CR25","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix CC, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020;4:2871\u201383.","journal-title":"Blood Adv"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02822-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02822-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02822-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:44:24Z","timestamp":1778154264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02822-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2822"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02822-z","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The investigation was approved by the Local Ethics Committee of the Medical Faculty of the University of Zurich, University Hospital Zurich (BASEC-Nr. 2023\u201302233).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The project was conducted in accordance with the Declaration of Helsinki, and all patients provided general consent for scientific analysis. Patients refusing consent for scientific analysis were excluded.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}